type
interferonopathi
new
class
disord
link
upregul
type
interferon
ifn
stimul
ifn
gene
sting
associ
vasculopathi
onset
infanc
savi
caus
gain
function
mutat
lead
constitut
product
high
level
type
ifn
without
infecti
trigger
savi
character
system
inflamm
chronic
anemia
growth
failur
cutan
necrot
lesion
interstiti
lung
diseas
lowtit
autoantibodi
ie
antinuclear
antibodi
anticardiolipin
antibodi
also
present
therapeut
manag
challeng
steroid
partial
effect
patient
respond
poorli
diseasemodifi
therapi
methotrex
mycophenol
mofetil
antimalari
infliximab
rituximab
prognosi
poor
especi
patient
sever
lung
involv
high
mortal
first
two
decad
life
light
encourag
result
obtain
use
jak
inhibitor
interferonopathi
abil
block
type
ifn
pathway
activ
savi
pbmc
vitro
savi
patient
treat
inhibitor
good
respons
describ
three
savi
patient
sever
pulmonari
involv
treatment
inhibitor
ruxolitinib
led
mark
amelior
diseas
manifest
sustain
one
patient
transient
two
local
ethic
committe
giannina
gaslini
institut
ospedal
pediatrico
bambin
approv
studi
ifn
signatur
perform
describ
minor
modif
briefli
rna
extract
whole
blood
peripher
venipunctur
drawn
paxgen
tube
use
paxgen
blood
rna
kit
qiagen
hilden
germani
cdna
retrotranscrib
use
cdna
synthesi
kit
invitrogen
carlsbad
california
usa
select
ifnstimul
gene
express
quantifi
realtim
pcr
use
genespecif
primer
probe
roch
ddct
method
rel
healthi
donor
calibr
use
hprt
refer
gene
case
sampl
run
differ
assay
healthi
donor
calibr
use
posit
control
ad
assess
interassay
variabl
mutat
gene
assess
standard
sanger
sequenc
target
resequenc
use
custom
panel
analyz
nextseq
sequenc
platform
illumina
san
diego
california
usa
sequenc
analyz
use
bioinformat
pipelin
integr
basespac
illumina
system
variant
call
variantstudio
softwar
variant
identifi
nextgener
sequenc
valid
sanger
sequenc
dyspnea
score
defin
follow
absenc
dyspnea
dyspnea
intens
physic
activ
gymnast
school
dyspnea
moder
physic
activ
climb
step
dyspnea
walk
dyspnea
rest
patient
current
age
year
old
born
healthi
unrel
parent
present
age
eight
month
isol
erythematosusinfiltr
skin
lesion
pustular
evolut
follow
scar
chilblain
sever
nail
dystrophi
three
year
age
fig
skin
biopsi
activ
nummular
violac
lesion
scar
resolut
preexist
lesion
reveal
granulomat
nodular
dermat
deep
granulomat
follicul
secondari
fibrosi
child
present
recurr
episod
bronchospasm
recurr
fever
episod
worsen
skin
lesion
age
eight
year
focal
thicken
interlobular
septa
area
ground
glass
opac
predomin
subpleur
distribut
evid
chest
ct
fig
lung
biopsi
reveal
lymphocyt
aggreg
peribronchi
interstiti
area
aspect
capillar
contigu
focal
subatelectasi
macrophag
infiltr
alveoli
tabl
immunolog
studi
reveal
increas
igg
ige
normal
lymphocyt
subset
distribut
normal
lymphocyt
prolifer
respons
mitogen
tetanu
toxoidspecif
igg
protect
level
test
nine
year
age
tabl
spirometri
reveal
mix
restrict
obstruct
featur
fig
tabl
differ
case
describ
far
mild
renal
involv
microscop
hematuria
mild
proteinuria
biopsi
perform
also
present
associ
hypertens
steroid
prednison
mgkgday
amelior
clinic
manifest
normal
inflammatori
marker
howev
diseas
relaps
observ
steroid
taper
azathioprin
etanercept
ineffect
peripher
blood
type
ifn
signatur
reveal
activ
type
ifninduc
gene
express
supplementari
fig
sanger
sequenc
gene
identifi
de
novo
mutat
patient
current
age
ten
year
old
recent
describ
present
age
three
month
growth
failur
respiratori
distress
tabl
livedo
reticulari
present
lower
limb
fig
patient
requir
sever
icu
admiss
ventil
support
lower
airway
infect
bronchiol
pneumonia
ct
scan
show
extens
ground
glass
abnorm
fig
chronic
pseudomona
aeruginosa
infect
document
lung
biopsi
show
interstiti
fibrosi
without
sign
vascul
echocardiograph
imag
show
indirect
sign
pulmonari
hypertens
mild
dilat
pulmonari
arteri
steroid
partial
effect
associ
methotrex
infliximab
ineffect
result
steroid
depend
daili
oxygen
support
noninvas
ventil
night
requir
cheek
nose
telangiectat
skin
lesion
unilater
vocal
cord
paresi
also
observ
fig
tabl
tabl
except
elev
total
iga
igg
mild
lymphopenia
immunolog
studi
reveal
major
alter
tabl
peripher
blood
type
ifn
signatur
posit
supplementari
fig
target
sequenc
reveal
mutat
patient
current
age
three
year
old
child
healthi
unrel
parent
present
three
day
life
erythematosu
vesicular
rash
nose
cheek
later
spread
hand
feet
evolut
pustul
scar
fig
tabl
admit
age
three
month
recurr
lowgrad
fever
cough
diarrhea
dermat
variabl
respons
glucocorticoid
antibiot
suspect
combin
immunodefici
skin
biopsi
consist
neutrophil
dermatosi
karyorrhexi
throughout
vessel
wall
fig
chest
ct
reveal
focal
thicken
interlobular
septa
area
ground
glass
opac
blood
investig
reveal
microcyt
anemia
increas
acutephas
reactant
hypergammaglobulinemia
mild
reduct
level
lowtit
autoantibodi
anticardiolipin
normal
distribut
lymphocyt
subset
lymphocyt
prolifer
normal
respons
pha
low
present
respons
tabl
peripher
blood
type
ifn
signatur
posit
supplementari
fig
patient
start
glucocorticoid
mgkgday
prednison
improv
clinic
laboratori
find
recurr
symptom
taper
target
genom
sequenc
reveal
de
novo
heterozyg
mutat
g
treatment
ruxolitinib
start
initi
mgkgday
two
dose
subsequ
progress
increas
clinic
efficaci
obtain
name
mgkgday
mgkgday
mgkgday
patient
show
initi
clinic
respons
start
first
week
treatment
evid
three
month
fig
tabl
amelior
lung
diseas
assess
pulmonari
function
test
ct
scan
resolut
cutan
lesion
stabl
transient
furthermor
show
resolut
microhematuria
abl
progress
taper
steroid
stop
two
year
also
show
amelior
skin
phenotyp
reduct
dyspnea
correl
improv
walk
test
satur
end
test
improv
increas
total
forc
vital
capac
fig
b
b
tabl
furthermor
echocardiograph
improv
indirect
sign
pulmonari
hypertens
document
normal
pulmonari
arteri
size
initi
show
good
clinic
respons
amelior
skin
lesion
radiolog
lung
find
fig
tabl
notabl
clinic
respons
correl
decreas
type
ifn
signatur
improv
transient
concomit
treatment
high
dose
steroid
ruxolitinib
fig
three
year
ruxolitinib
treatment
present
three
flare
skin
lesion
requir
brief
cycl
steroid
sever
infect
occur
bk
viru
urin
intermitt
detect
viral
copi
thousand
millionml
without
bk
viremia
alter
kidney
function
followup
month
start
seven
month
therapi
experienc
increas
hospit
respiratori
infect
caus
pseudomona
aeruginosa
exacerb
sever
episod
rhinoviru
infect
influenza
varicella
coronaviru
last
requir
mechan
ventil
extracorpor
membran
oxygen
day
prompt
decis
reduc
ruxolitinib
dosag
fig
month
therapi
ct
scan
reveal
worsen
interstiti
diseas
ground
glass
appear
interlobular
thicken
fig
followup
month
ten
month
treatment
ruxolitinib
present
clinic
radiolog
relaps
lung
diseas
requir
glucocorticoid
therapi
mgkgday
prednison
prompt
respons
fig
never
present
viral
bacteri
infect
sinc
begin
therapi
cell
blood
count
ruxolitinib
serum
level
regularli
monitor
supplementari
fig
supplementari
tabl
cytopenia
observ
followup
tabl
patient
continu
ruxolitinib
treatment
time
write
report
confirm
jak
inhibit
therapeut
resourc
worth
consid
patient
savi
includ
young
children
case
also
take
account
diseas
poorli
respond
avail
immunemodifi
agent
howev
contrari
publish
report
observ
sever
episod
sever
viral
infect
one
patient
suggest
possibl
jak
inhibitor
might
significantli
increas
risk
infect
possibl
case
sever
lung
involv
presenc
genet
modifi
investig
patient
consequ
deterior
lung
diseas
interestingli
frequent
viru
isol
rhinoviru
may
direct
consequ
effect
type
ifn
inhibit
ruxolitinib
least
respiratori
epitheli
cell
requir
control
rhinoviru
end
infect
might
result
cumul
effect
drug
report
development
vitro
prolif
defect
sting
mutant
lymphocyt
consid
sever
lung
diseas
lymphopenia
tabl
present
ruxolitinib
treatment
start
antibiot
prophylaxi
bactrim
azithromycin
howev
seem
prevent
febril
episod
mostli
alway
caus
viral
pathogen
note
patient
ivig
prophylaxi
sever
infect
report
far
whether
due
ruxolitinib
reduct
andor
ivig
treatment
difficult
understand
observ
variabl
medium
longterm
clinic
respons
therapi
seem
reach
stabl
control
diseas
requir
point
introduct
increas
steroid
control
flare
sever
factor
might
play
role
includ
variabl
diseas
sever
inadequ
plasma
drug
level
inde
patient
steroid
depend
requir
sever
hospit
admiss
treat
flare
appear
sever
phenotyp
present
sever
lifethreaten
exacerb
requir
admiss
icu
ventil
support
infect
episod
present
earli
diseas
onset
three
day
life
addit
despit
dose
adjust
plasma
level
monitor
drug
dosag
appear
stabli
adequ
supplementari
fig
supplementari
tabl
notabl
reduc
ruxolitinib
dosag
one
year
therapi
attempt
prevent
infect
fig
overexpress
set
interferonstimul
gene
isg
peripher
blood
consist
found
report
patient
savi
syndrom
modul
ifn
signatur
follow
treatment
may
repres
surrog
biomark
howev
observ
consist
decreas
ifn
signatur
treatment
previou
report
ruxolitinib
treatment
patient
savi
partial
decreas
ifn
signatur
observ
lack
downregul
ifn
signatur
might
explain
fast
kinet
jak
inhibit
ruxolitinib
shown
transient
decreas
follow
drug
intak
seem
coupl
clear
impact
isg
express
supplementari
fig
otherwis
might
suggest
six
test
appropri
assess
type
interferon
activ
least
patient
savi
treat
jak
inhibitor
final
import
consid
ruxolitinib
inhibit
signal
type
interferon
receptor
also
receptor
involv
import
inflammatori
pathway
interferon
possibl
inhibit
pathway
respons
therapeut
efficaci
side
effect
see
savi
conclus
savi
diseas
still
appear
orphan
ideal
therapeut
target
despit
encourag
result
obtain
previou
report
prospect
studi
greater
number
patient
warrant
address
crucial
issu
link
jak
inhibitor
use
patient
savi
